MedTrace Logo

Efficacy and Safety of Secukinumab in Conjunction With Surgery in Moderate to Severe Hidradenitis Suppurativa

NCT06926192 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2025-04-16

No results posted yet for this study

Summary

This study aims to retrospectively analyze the efficacy and safety of secukinumab combined with surgery in treating moderate to severe HS in real-world clinical practice, providing clinical practioners with real-world evidence in HS treatment.

Conditions

  • Hidradenitis Suppurativa (HS)
  • Hidradenitis Suppurativa (Acne Inversa)
  • Secukinumab

Interventions

COMBINATION_PRODUCT

Surgery combined with secukinumab

Surgery combined with secukinumab

Sponsors & Collaborators

  • Peking Union Medical College

    lead OTHER

Eligibility

Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-01
Primary Completion
2024-12-31
Completion
2025-06-21

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06926192 on ClinicalTrials.gov